Imaging mass spectrometry: Towards clinical diagnostics

Seeley, Erin H.; Caprioli, Richard M.

doi:10.1002/prca.200800013

Cited by 44 publications

(30 citation statements)

References 39 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early data on liver cancer showed the ability to discriminate between healthy and diseased tissue based on their characteristic lipid profiles. 57) Subsequent studies on other cancers have confirmed these findings.…”

Section: )supporting

confidence: 67%

Through a Glass Darkly: Glimpses into the Future of Mass Spectrometry

Cooks

Mueller

2013

Mass Spectrometry

View full text Add to dashboard Cite

The paper has three parts, (i) a brief overview of the main achievements made using mass spectrometry across all the fields of science, (ii) a survey of some of the topics currently being pursued most activity, including both applications and fundamental studies, and (iii) some hints as to what the future of mass spectrometry might hold with particular emphasis on revolutionary changes in the subject. Emphasis is given to ambient methods of ionization and their use in disease diagnosis and to their use in combination with miniature mass spectrometers for in-situ measurements. Special attention goes to the chemical aspects of mass spectrometry, including its emerging role as a preparative method based on accelerated bimolecular reaction rates in solution and on ion soft landing as a means of surface tailoring. In summary, the paper covers the proud history, vibrant present and expansive future of mass spectrometry.Keywords: ion chemistry, history of mass spectrometry, reaction rates, ion reactivity, mechanisms, instrumentation (Received October 12, 2012; Accepted October 16, 2012) Mass spectrometry may be defined, broadly, as the science and technology of ions. As such, it is a subject of enormous scope. The achievements of 20th century mass spectrometry now have come into focus. In rapid succession these include the measurement of mass/charge ratios of ions, 1) the discovery of isotopes, 2) and the utilization of isotope ratio measurements, 3) the measurements of mass defects, 4) and fundamental understanding of ionization, 5) fragmentation mechanisms 6) and the measurement of bond energies. 7) All this was achieved in the first half of the century and was made possible by advances in instrumentation including ionization methods, detectors and most importantly mass analyzers such as double focusing sector instruments. In the second half-century, organic mass spectrometry grew rapidly, starting with applications to petroleum distillates and moving quickly to natural products, steroids, and small-molecule drugs. 8) Gas chromatography/mass spectrometry was a key technology in early studies of biological systems. 9) Advances in instrumentation again fueled these advances, with ion optics becoming a significant scientific technology especially in Japan.10) A preoccupation with improving mass resolution and mass range became established and different types of mass analyzers were introduced for this purpose, including time-of-flight instruments 11) and quadrupole ion traps. 12) This quest drove biological mass spectrometry and propelled the development of ionization methods that were increasingly successful in handling both solid samples (desorption methods) 13)

show abstract

Section: )supporting

confidence: 67%

Through a Glass Darkly: Glimpses into the Future of Mass Spectrometry

Cooks

Mueller

2013

Mass Spectrometry

View full text Add to dashboard Cite

show abstract

“…Since the concept of directly identifying molecules on tissues using MALDI ion sources was proposed at the end of the 1990s (Caprioli et al 1997), MALDI imaging mass spectrometry has been used in many clinical applications (Cornett et al 2006;El Ayed et al 2010;Lemaire et al 2006a, b;Pevsner et al 2009;Schwamborn et al 2007;Schwartz et al 2004;Seeley and Caprioli 2008). A decade of developments in instrumentation and chemistry has been required to achieve optimal extraction, detection, and spatial resolution when mapping compounds at the tissue level (Franck et al 2009a, b;Lemaire et al 2006a, b;2007a;van Remoortere et al 2010).…”

Section: Introductionmentioning

confidence: 99%

The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling

Longuespée

Boyon

Castellier

et al. 2012

Histochem Cell Biol

View full text Add to dashboard Cite

This study reports on the C-terminal fragment of the 11S proteasome activator complex (PA28 or Reg alpha), a novel ovarian-specific biomarker of early and late stages of ovarian cancer (OVC) relapse, in patient biopsies after chemotherapy. A total of 179 tissue samples were analyzed: 8 stage I, 55 stage III-IV, 10 relapsed serous carcinomas, 25 mucinous carcinomas and 12 borderline and 68 benign ovarian tissue samples. This fragment was detected by MALDI mass spectrometry profiling in conjunction with a novel extraction method using hexafluoroisopropanol (1,1,1,3,3,3-hexafluoro-2-propanol; HFIP) solvents for protein solubilization and by immunohistochemistry using a specific antibody directed against the C-terminal fragment of PA28. Due to its specific cellular localization, this fragment is a suitable candidate for early OVC diagnosis, patient prognosis and follow-up during therapy and discriminating borderline cancers. Statistical analyses performed for this marker at different OVC stages reflect a prevalence of 77.66 ± 8.77 % (with a correlation coefficient value p \ 0.001 of 0.601 between OVC and benign tissue). This marker presents a prevalence of 88 % in the case of tumor relapse and is detected at 80.5 % in stage I and 81.25 % ± 1.06 in stage III-IV of OVC. The correlation value for the different OVC stages is p \ 0.001 of 0.998. Taken together, this report constitutes the first evidence of a novel OVC-specific marker.

show abstract

“…Its potential to reveal the distribution of hundreds of molecules in a single measurement, without prior derivatization, is especially useful for the clinicopathologic analysis of cancer (16)(17)(18). Desorption electrospray ionization (DESI) MSI allows the detection of small metabolites and complex lipids within a tissue sample (19,20).…”

Section: Introductionmentioning

confidence: 99%

Spatially Resolved Metabolic Phenotyping of Breast Cancer by Desorption Electrospray Ionization Mass Spectrometry

et al. 2015

View full text Add to dashboard Cite

Breast cancer is a heterogeneous disease characterized by varying responses to therapeutic agents and significant differences in long-term survival. Thus, there remains an unmet need for early diagnostic and prognostic tools and improved histologic characterization for more accurate disease stratification and personalized therapeutic intervention. This study evaluated a comprehensive metabolic phenotyping method in breast cancer tissue that uses desorption electrospray ionization mass spectrometry imaging (DESI MSI), both as a novel diagnostic tool and as a method to further characterize metabolic changes in breast cancer tissue and the tumor microenvironment. In this prospective single-center study, 126 intraoperative tissue biopsies from tumor and tumor bed from 50 patients undergoing surgical resections were subject to DESI MSI. Global DESI MSI models were able to distinguish adipose, stromal, and glandular tissue based on their metabolomic fingerprint. Tumor tissue and tumor-associated stroma showed evident changes in their fatty acid and phospholipid composition compared with normal glandular and stromal tissue. Diagnosis of breast cancer was achieved with an accuracy of 98.2% based on DESI MSI data (PPV 0.96, NVP 1, specificity 0.96, sensitivity 1). In the tumor group, correlation between metabolomic profile and tumor grade/hormone receptor status was found. Overall classification accuracy was 87.7% (PPV 0.92, NPV 0.9, specificity 0.9, sensitivity 0.92). These results demonstrate that DESI MSI may be a valuable tool in the improved diagnosis of breast cancer in the future. The identified tumor-associated metabolic changes support theories of de novo lipogenesis in tumor tissue and the role of stroma tissue in tumor growth and development and overall disease prognosis. Cancer Res; 75(9); 1828-37. Ó2015 AACR.

show abstract

Imaging mass spectrometry: Towards clinical diagnostics

Cited by 44 publications

References 39 publications

Through a Glass Darkly: Glimpses into the Future of Mass Spectrometry

Through a Glass Darkly: Glimpses into the Future of Mass Spectrometry

The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling

Spatially Resolved Metabolic Phenotyping of Breast Cancer by Desorption Electrospray Ionization Mass Spectrometry

Contact Info

Product

Resources

About